Elan revenues in first quarter boosted by Tysabri MS drug; Loss decreased by 8% to $85.5 million
May 22nd, 2008 | By Finfacts Ireland Business & Finance Portal | Category: News worldwide
Elan Corporation, today announced its first quarter 2008 financial results, which were boosted by Tysabri sales and provided a business update.